274 related articles for article (PubMed ID: 19167683)
1. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation.
Bartelink IH; Bredius RG; Belitser SV; Suttorp MM; Bierings M; Knibbe CA; Egeler M; Lankester AC; Egberts AC; Zwaveling J; Boelens JJ
Biol Blood Marrow Transplant; 2009 Feb; 15(2):231-41. PubMed ID: 19167683
[TBL] [Abstract][Full Text] [Related]
2. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.
Bartelink IH; Bredius RG; Ververs TT; Raphael MF; van Kesteren C; Bierings M; Rademaker CM; den Hartigh J; Uiterwaal CS; Zwaveling J; Boelens JJ
Biol Blood Marrow Transplant; 2008 Jan; 14(1):88-98. PubMed ID: 18158965
[TBL] [Abstract][Full Text] [Related]
3. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation.
Ansari M; Théoret Y; Rezgui MA; Peters C; Mezziani S; Desjean C; Vachon MF; Champagne MA; Duval M; Krajinovic M; Bittencourt H;
Ther Drug Monit; 2014 Feb; 36(1):93-9. PubMed ID: 24061446
[TBL] [Abstract][Full Text] [Related]
4. Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
Zwaveling J; den Hartigh J; Lankester AC; Guchelaar HJ; Egeler RM; Bredius RG
Anticancer Drugs; 2006 Oct; 17(9):1099-105. PubMed ID: 17001185
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.
Schechter T; Finkelstein Y; Doyle J; Verjee Z; Moretti M; Koren G; Dupuis LL
Biol Blood Marrow Transplant; 2007 Mar; 13(3):307-14. PubMed ID: 17317584
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation.
Kletzel M; Jacobsohn D; Duerst R
Biol Blood Marrow Transplant; 2006 Apr; 12(4):472-9. PubMed ID: 16545731
[TBL] [Abstract][Full Text] [Related]
7. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.
Bartelink IH; Lalmohamed A; van Reij EM; Dvorak CC; Savic RM; Zwaveling J; Bredius RG; Egberts AC; Bierings M; Kletzel M; Shaw PJ; Nath CE; Hempel G; Ansari M; Krajinovic M; Théorêt Y; Duval M; Keizer RJ; Bittencourt H; Hassan M; Güngör T; Wynn RF; Veys P; Cuvelier GD; Marktel S; Chiesa R; Cowan MJ; Slatter MA; Stricherz MK; Jennissen C; Long-Boyle JR; Boelens JJ
Lancet Haematol; 2016 Nov; 3(11):e526-e536. PubMed ID: 27746112
[TBL] [Abstract][Full Text] [Related]
8. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa).
Bouligand J; Boland I; Valteau-Couanet D; Deroussent A; Kalifa C; Hartmann O; Vassal G
Bone Marrow Transplant; 2003 Nov; 32(10):979-86. PubMed ID: 14595385
[TBL] [Abstract][Full Text] [Related]
9. Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation.
Wall DA; Chan KW; Nieder ML; Hayashi RJ; Yeager AM; Kadota R; Przepiorka D; Mezzi K; Kletzel M;
Pediatr Blood Cancer; 2010 Feb; 54(2):291-8. PubMed ID: 19743300
[TBL] [Abstract][Full Text] [Related]
10. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen.
Geddes M; Kangarloo SB; Naveed F; Quinlan D; Chaudhry MA; Stewart D; Savoie ML; Bahlis NJ; Brown C; Storek J; Andersson BS; Russell JA
Biol Blood Marrow Transplant; 2008 Feb; 14(2):220-8. PubMed ID: 18215782
[TBL] [Abstract][Full Text] [Related]
11. High-dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors.
Diaz MA; Vicent MG; Madero L
Bone Marrow Transplant; 1999 Dec; 24(11):1157-9. PubMed ID: 10642802
[TBL] [Abstract][Full Text] [Related]
12. Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling.
Lee JW; Kang HJ; Lee SH; Yu KS; Kim NH; Yuk YJ; Jang MK; Han EJ; Kim H; Song SH; Park KD; Shin HY; Jang IJ; Ahn HS
Biol Blood Marrow Transplant; 2012 Jun; 18(6):944-50. PubMed ID: 22155501
[TBL] [Abstract][Full Text] [Related]
13. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
Tran HT; Madden T; Petropoulos D; Worth LL; Felix EA; Sprigg-Saenz HA; Choroszy M; Danielson M; Przepiorka D; Chan KW
Bone Marrow Transplant; 2000 Sep; 26(5):463-70. PubMed ID: 11019834
[TBL] [Abstract][Full Text] [Related]
14. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity.
Zwaveling J; Bredius RG; Cremers SC; Ball LM; Lankester AC; Teepe-Twiss IM; Egeler RM; den Hartigh J; Vossen JM
Bone Marrow Transplant; 2005 Jan; 35(1):17-23. PubMed ID: 15502853
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation.
Tran H; Petropoulos D; Worth L; Mullen CA; Madden T; Andersson B; Choroszy M; Nguyen J; Webb SK; Chan KW
Biol Blood Marrow Transplant; 2004 Nov; 10(11):805-12. PubMed ID: 15505611
[TBL] [Abstract][Full Text] [Related]
16. Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation.
Ryu SG; Lee JH; Choi SJ; Lee JH; Lee YS; Seol M; Hur EH; Lee SH; Bae KS; Noh GJ; Lee MS; Yun SC; Han SB; Lee KH
Biol Blood Marrow Transplant; 2007 Sep; 13(9):1095-105. PubMed ID: 17697972
[TBL] [Abstract][Full Text] [Related]
17. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
18. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring.
Vassal G; Michel G; Espérou H; Gentet JC; Valteau-Couanet D; Doz F; Mechinaud F; Galambrun C; Neven B; Zouabi H; Nguyen L; Puozzo C
Cancer Chemother Pharmacol; 2008 Jan; 61(1):113-23. PubMed ID: 17393167
[TBL] [Abstract][Full Text] [Related]
19. Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman-Diamond syndrome.
Sauer M; Zeidler C; Meissner B; Rehe K; Hanke A; Welte K; Lohse P; Sykora KW
Bone Marrow Transplant; 2007 Feb; 39(3):143-7. PubMed ID: 17211437
[TBL] [Abstract][Full Text] [Related]
20. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
Bleyzac N; Souillet G; Magron P; Janoly A; Martin P; Bertrand Y; Galambrun C; Dai Q; Maire P; Jelliffe RW; Aulagner G
Bone Marrow Transplant; 2001 Oct; 28(8):743-51. PubMed ID: 11781625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
